Researchers at Whitehead Institute have developed a novel platform with human beta cells that could allow scientists to better understand the mechanisms underlying type 1 diabetes and what provokes it.
Whitney Henry is a postdoc in Whitehead Institute Founding Member Robert Weinberg’s lab investigating ways to target a type of cancer cell that is particularly prone to metastasis and resisting treatment.
This is the first proof of principle for using adult cells reprogrammed to an embryonic-stem-cell-like state, combined with gene and cell therapy, for successful disease treatment in mice.
Whitehead Associate Member David Sabatini has been chosen by the W.M. Keck Foundation as one of this year’s grant recipients under the Distinguished Young Scholars in Medical Research program.
